BEIJING, Nov. 23, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its abstract highlighting the potential of BGB-3111, a clinically differentiated, potent and highly selective small molecule BTK inhibitor, has been selected for presentation at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition. The conference will take place December 5–8 in Orlando, Florida, United States. Details for the presentation are provided below.
Title: The BTK Inhibitor, BGB-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial
Authors: Constantine Tam, Andrew P. Grigg, Stephen Opat, Matthew Ku, Michael Gilbertson, Mary Ann Anderson, John F. Seymour, David S. Ritchie, Carmen Dicorleto, Belinda Dimovski, Eric Hedrick, Jianxin Yang, Lai Wang, Lusong Luo, Ling Xue, Andrew W. Roberts
Presenter: Constantine Tam
Session: 642. CLL: Therapy, excluding Transplantation: Relapsed/Refractory CLL Therapy Excluding Transplantation
Date: Monday, December 7, 2015
Time: 5:15 PM EST
Location: Orange County Convention Center, Valencia BC (W415BC)
BeiGene is a global, clinical-stage, research-based company focused on targeted and immuno-oncology therapeutics. With a team of 190+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions that will have both a meaningful and lasting impact on cancer patients. For more information, please visit our website at www.beigene.com.
CONTACT: Media/Investor Contact: Xin Huang US: +1 917-617-4653 China: +86 185-1406-3050 email@example.com